4D Molecular Therapeutics (FDMT) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Income towards Parent Company fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Income towards Parent Company is -$56.9 million, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Income towards Parent Company peaked at -$7.6 million during Q2 2021, and registered a low of -$56.9 million during Q3 2025.
- For the 5-year period, 4D Molecular Therapeutics' Income towards Parent Company averaged around -$31.6 million, with its median value being -$28.7 million (2023).
- Per our database at Business Quant, 4D Molecular Therapeutics' Income towards Parent Company soared by 6070.82% in 2023 and then plummeted by 33416.52% in 2024.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Income towards Parent Company stood at -$25.1 million in 2021, then dropped by 9.2% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then fell by 14.51% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$54.6 million for Q2 2025, and -$48.0 million during Q1 2025.